A federal court invalidated HRSA’s orphan drug policy and limited the agency’s ability to expand the 340B Drug Pricing Program through regulation or guidance. The ruling means manufacturers cannot be required to provide a 340B discount based on the condition a drug treats when that drug has an official orphan designation. Under the court’s interpretation, the designation controls.
The issue affects how manufacturer pricing obligations connect with the budgets of clinics and hospitals that serve vulnerable and low-income populations. A covered entity that obtains a discount may use the savings to support its operating budget. Whether a discount applies therefore concerns both the scope of agency authority and the resources available to organizations that provide outpatient care.
How the orphan drug exception works
The 340B program requires pharmaceutical manufacturers to offer outpatient drugs at discounted prices to eligible healthcare organizations known as covered entities. These organizations typically serve vulnerable and low-income patients across the country. Their savings from the discounts help them manage operating expenses.
Congress created a specific orphan drug exception under the statutory text in the United States Code. The exception removes mandatory 340B pricing discounts for drugs designated to treat rare diseases. The legislative goal was to protect financial incentives for manufacturers that develop specialized treatments for rare conditions such as ALS.
The dispute concerned the application of that exception when an orphan drug was prescribed for a common indication. HRSA sought to require a manufacturer to offer the 340B discount in that situation. The agency treated the patient’s diagnosis as the deciding factor. Under HRSA’s position, a manufacturer could not rely on the drug’s orphan designation to withhold the discount when the medication was used for a standard condition.
That interpretation would have created an additional pricing obligation for manufacturers. It also could have expanded covered entities’ access to discounted products and increased the savings available for their operations. The dispute involved the statutory rules for manufacturer discounts. It did not automatically determine the price that an individual patient would pay.
Why the court rejected the policy
The Pharmaceutical Research and Manufacturers of America, known as PhRMA, challenged HRSA’s initial action in federal court. The organization argued that HRSA did not have explicit legislative authority to define the statutory exception in this manner.
A federal judge agreed that the agency had gone beyond its regulatory authority. After losing that case, HRSA withdrew its pending Omnibus 340B rule from administrative consideration. The agency then issued the orphan drug policy again as an interpretation of the statute rather than as a legislative rule. HRSA administrators hoped that changing the policy’s form would protect it from another legal challenge.
The change did not settle the underlying question. PhRMA filed another lawsuit, and Judge Rudolph Contreras rejected HRSA’s defense. The court found that the interpretive rule imposed specific duties on manufacturers. Calling the policy an interpretation did not alter its practical effect. The document still told manufacturers to provide discounts in situations where HRSA believed the statute required them to do so.
The court invalidated the policy because it conflicted with the statute’s plain language. The statutory exemption applies to a drug based on its official FDA orphan designation. The exemption does not depend on how a patient ultimately uses the medication. HRSA therefore cannot legally require a manufacturer to provide a 340B discount based on the particular condition being treated.
The designation versus the use
The court’s main distinction concerns the difference between a drug’s designation and its use. HRSA focused on the indication involved in a specific prescription. The court focused on the drug’s official designation.
Under HRSA’s approach, the same product could receive different treatment depending on whether a healthcare provider prescribed it for a rare disease or a common condition. Under the court’s interpretation, the orphan exception follows the drug’s designation. The statute does not allow HRSA to add a condition based on use.
Medication costs can also depend on the relationship between a product and its approved uses. The Wegovy cost guide explains how separate brand names for separate approved indications can affect what a health plan pays and what a pharmacy charges, even when the molecule remains the same.
What the ruling means for future guidance
The decision leaves uncertainty about other HRSA guidance documents. Its reasoning gives manufacturers and covered entities a basis for challenging agency directives that impose duties beyond the authority Congress provided.
Possible disputes include guidance about contract pharmacy audits and patient definitions. If later HRSA guidance creates new compliance duties without direct congressional authorization, the reasoning in this case suggests that the guidance could face immediate litigation.
The ruling sets a limit on HRSA’s role. The agency may administer the 340B program, but it cannot use a rule or interpretive document to add conditions that do not appear in the statutory text. HRSA may therefore need to reduce the scope of its regulatory efforts to avoid further defeats in court.
Congressional action may be the only viable way to resolve wider disputes about the program. Lawmakers have shown increased interest through committee hearings and requests for formal investigations. Until Congress changes the law, federal courts will remain the main forum for deciding the scope of the 340B program and the obligations it creates.